Switch to fixed-dose doravirine (100 mg) and islatravir (0·25 mg) once daily in virologically suppressed adults with HIV-1 on oral antiretroviral therapy: 48-week results of a phase 3, multicentre, randomised, open-label, non-inferiority trial

Zurich Open Repository and Archive (University of Zurich) 2026

View at publisher
Authors: Chloe; https://orcid.org/0000-0001-6168-6745 Orkin, Rosie; https://orcid.org/0000-0002-6540-5733 Mngqibisa, Juan D. Vélez, Princy; https://orcid.org/0000-0002-5994-2727 Kumar, Dominique L; https://orcid.org/0000-0003-4036-1030 Braun, Andrew Carr, Mark; https://orcid.org/0000-0002-1143-5013 Bloch, Sharon; https://orcid.org/0000-0002-3959-5692 Walmsley, Pablo; https://orcid.org/0000-0001-5345-7942 Tebas, Yoshiyuki; https://orcid.org/0000-0002-6342-544X Yokomaku, Tracy L. Diamond, Beth Jackson
+7 more Karen; https://orcid.org/0009-0004-8626-2753 Eves, Anjana; https://orcid.org/0000-0001-7339-8740 Grandhi, Monica; https://orcid.org/0009-0006-6724-0676 Fuszard, Stephanie Olsen Klopfer, Luisa M. Stamm, Michelle C Fox, Jason Kim
DOI: 10.1016/s0140-6736(25)01945-2
Cited by: 1

Fields of Study & Subjects

HIV/AIDS drug development and treatment HIV-related health complications and treatments HIV/AIDS Research and Interventions

Publication details

Journal / source
Zurich Open Repository and Archive (University of Zurich)
Publication date
7 February 2026
Language
EN